Pseudomyxoma peritonei (PMP) is a rare and uncommon cancer.
The definition of both rare and uncommon varies from country to country. In Australia and in the UK, the definition of a rare cancer is one that has less than 6 incidences per year per 100,000 population whilst in the USA, cancer that occurs in fewer than 15 out of 100,000 people each year is deemed to be rare, as defined by the National Cancer Institute. Occurring in around 3-4 people per million each year, PMP certainly falls within the parameters of rare no matter which definition you use.
An uncommon or less common cancer is generally agreed to mean cancers that are not of the lung, breast, bowel and prostate (the four most common). Again, as PMP most usually originates from an appendix tumour, it is included as an uncommon cancer.
Written by: A Brook
Reviewed by: Dr G Morgan MB ChB
July 2019
More FAQs
Tumour markers CEA, CA125 and CA19-9, what are they and what do they mean?
A tumour marker is a substance of the blood that appears at a higher level than expected in your blood, in your urine or in a sample of your tissue. They may be produced by the presence of cancerous cells or by perfectly healthy cells.
What are some of the factors that can impact the prognosis for PMP?
There are several factors that can impact the prognosis for Pseudomyxoma peritonei (PMP), including the histological grade of the tumour
What are the benefits of HIPEC?
HIPEC stands for “Hyperthermic Intraperitoneal Chemotherapy” and follows cytoreductive surgery (CRS).
References
Estimating the Prevalence of Pseudomyxoma Peritonei in Europe...
Patrick-Brown, T.D.J.H., Carr, N.J., Swanson, D.M. et al (2020). Estimating the Prevalence of Pseudomyxoma Peritonei in Europe Using a Novel Statistical Method. Ann Surg Oncol (2020). Retrieved on May 28, 2022, from doi:10.1245/s10434-020-08655-8.